Development of Novel Alternative Serotype Adenoviral Vectors for Gene Delivery in

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43DC010291-01
Agency Tracking Number: DC010291
Amount: $138,699.00
Phase: Phase I
Program: SBIR
Awards Year: 2009
Solicitation Year: 2009
Solicitation Topic Code: N/A
Solicitation Number: PHS2009-2
Small Business Information
GENVEC, INC.
GENVEC, INC., 65 W WATKINS MILL RD, GAITHERSBURG, MD, 20878
DUNS: 806729547
HUBZone Owned: Y
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 DOUGLAS BROUGH
 (240) 632-5540
 DBROUGH@GENVEC.COM
Business Contact
  WEST
Phone: (240) 632-5537
Email: dbrough@genvec.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Myriad studies have examined the potential of gene therapy in the inner ear. For the most part they have focused on adenoviral vectors and delivery into the cochlea. Most studies have emphasized looking at expression of marker genes driven by a CMV promoter and have used first generation adenoviral constructs based on the adenovirus serotype Ad5. The main advantages of the adenoviral delivery system are efficient gene delivery to most target tissues, the ease of synthesis and the ability to redirect adenoviral vectors to a variety of cell types and the advanced use of the vector system in the clinic. The main disadvantages of the current adenoviral delivery system is that gene delivery is not targeted for entry into specific cells in the inner ear and the Ad5 based vectors are strongly immunologically recognized in the human population. The proposed studies will test the hypothesis that adenoviral vectors based on non- Ad5 serotypes incorporating cell type specific promoters can be used to efficiently and specifically deliver proteins to the sensory cells and supporting cells of the inner ear. These new adenovirus vectors will overcome the limitations to the current Ad5 based system. During SBIR phase I we will first characterize and select novel adenoviral vector platforms that efficiently deliver genes to the inner ear and second test preferred vectors for selective expression in sensory cells and in supporting cells using specific promoter control elements. With these results in hand and the ever increasing genomic findings molecular therapeutics can be designed and tested that may treat inner ear disease. PUBLIC HEALTH RELEVANCE: This SBIR Phase 1 proposal tests the hypothesis that adenoviral vectors based on non- Ad5 serotypes incorporating cell type specific promoters can be used to efficiently and specifically deliver proteins to the sensory cells and supporting cells of the inner ear. These new adenovirus vectors will overcome the limitations to the current Ad5 based system. We will first characterize and select novel adenoviral vector platforms that efficiently deliver genes to the inner ear and second test preferred vectors for selective expression in sensory cells and in supporting cells using specific promoter control elements.

* information listed above is at the time of submission.

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government